相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名:
InVivoMAb Anti-SARS-CoV-2 RBD (KP.2) Neutralizing Antibody (Iv0263)
- 抗体英文名:
InVivoMAb Anti-SARS-CoV-2 RBD (KP.2) Neutralizing Antibody (Iv0263)
- 浓度:
1 mg/ml
- 应用范围:
ELISA, Neutralization
- 宿主:
Human
- 保质期:
1 year
- 级别:
科研级
- 库存:
999
- 供应商:
AntibodySystem
- 克隆性:
Monoclonal
- 亚型:
IgG1, kappa
- 规格:
100ug

| 宿主 | Human |
| 种属反应性 | SARS-CoV-2 (2019-nCoV) |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 浓度 | 1 mg/ml |
| 纯度 | >95% as determined by SDS-PAGE. |
| 克隆类型 | Monoclonal |
| 同种型 | IgG1, kappa |
| 应用 | ELISA, Neutralization |
| 靶标 | Spike glycoprotein, S glycoprotein, E2, Peplomer protein, RBD, Spike protein S1, S, Receptor-Binding Domain, RBD (KP.2) |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 内毒素水平 | Please contact with the lab for this information. |
| Accession号 | P0DTC2 |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| 克隆号 | Iv0263 |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
AntibodySystem products span research areas including 48 viruses, superbugs, parasites, cancer, Alzheimer's, Parkinson's, allergic and hypersensitivity reactions, immune suppression, and immune activation.
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Neutralizing Bioassay Protocols
describe in vitro bioassays using neutralizing anti-mouse and anti-human cytokine antibodies. In general, the cytokine bioassay protocols are modified to pre-incubate the cytokine of interest with the specific neutralizing antibody prior to addition
中科院高福院士课题组 2020 年发表了哪些重要的研究成果?
:Science 9、Science 后再发 Nature!筛选出又一新冠病毒治疗性单克隆中和抗体DOI: 10.1038/s41586-020-2381-y继之前发表在 Science 上报道筛选出新冠病毒中和抗体后,2020 年 5 月 26 日,高福院士再次联合严景华等人在 Nature 发文:A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2。该研究报告了从 COVID-19 恢复期的患者中分离出两
neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Preprint at bioRxiv 11: Lynch, KL et al. (2020) Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Preprint
技术资料暂无技术资料 索取技术资料









